GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (LTS:0I0X) » Definitions » 3-Year EPS without NRI Growth Rate

Codexis (LTS:0I0X) 3-Year EPS without NRI Growth Rate : -39.10% (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Codexis 3-Year EPS without NRI Growth Rate?

Codexis's EPS without NRI for the three months ended in Dec. 2024 was $-0.13.

During the past 3 years, the average EPS without NRI Growth Rate was -39.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -60.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Codexis was 71.70% per year. The lowest was -102.10% per year. And the median was -18.20% per year.


Competitive Comparison of Codexis's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Codexis's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Codexis's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codexis's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Codexis's 3-Year EPS without NRI Growth Rate falls into.


;
;

Codexis 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Codexis  (LTS:0I0X) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Codexis 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Codexis's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Codexis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (LTS:0I0X) » Definitions » 3-Year EPS without NRI Growth Rate
Traded in Other Exchanges
Address
200 Penobscot Drive, Redwood City, CA, USA, 94063
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Codexis Headlines

No Headlines